Patents by Inventor Michel Revel

Michel Revel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL6R/IL6 chimera for therapy of chemotherapy-induced peripheral neuropathy
    Patent number: 8394367
    Abstract: The invention relates to the use of IL-6R/IL-6 chimera in chemotherapy induced neuropathy.
    Type: Grant
    Filed: April 28, 2005
    Date of Patent: March 12, 2013
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: Michel Revel, Judith Chebath, Hagit Krug
  • IL6R/IL6 Chimera for Therapy of Chemotherapy-Induced Peripheral Neuropathy
    Publication number: 20110274647
    Abstract: The invention relates to the use of IL-6R/IL-6 chimera in chemotherapy induced neuropathy.
    Type: Application
    Filed: April 28, 2005
    Publication date: November 10, 2011
    Applicant: Yeda Research and Development Co., Ltd.
    Inventors: Michel Revel, Judith Chebath, Hagit Krug
  • Use of il6r/il6 chimera in nerve cell regeneration
    Patent number: 7824670
    Abstract: The present invention provides for the use of IL6R/IL6 chimera for the manufacture of medicaments for the treatment of neurological diseases and disorders.
    Type: Grant
    Filed: December 31, 2002
    Date of Patent: November 2, 2010
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: Shalom Haggiag, Michel Revel, Judith Chebath, Alon Levy, Peilin Zhang
  • Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns
    Publication number: 20100003751
    Abstract: A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity.
    Type: Application
    Filed: August 15, 2007
    Publication date: January 7, 2010
    Applicant: Yeda Research and Development Co., Ltd.
    Inventors: Michel Revel, Judith Chebath, Michal Izrael, Rosalia Kaufman
  • IFN receptor 1 binding proteins
    Patent number: 7524928
    Abstract: Novel proteins IR1B1 and IR1B4 have been isolated which bind to the type I IFN receptor IFNAR1 and function in the cellular response to IFNs. DNA encoding such proteins in either the sense or anti-sense orientation can be administered to either enhance or inhibit the cellular response to IFNs. Antibodies to the proteins can be used for isolation of the new protein or for immunodetection thereof.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: April 28, 2009
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: Michel Revel, Carolina Abramovitch, Judith E. Chebath
  • Nucleic acids encoding chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof
    Patent number: 7374912
    Abstract: Chimeric proteins constructed from the fusion of the naturally occurring form of the soluble IL-6 receptor and IL-6 which are useful for treatment of cancer and liver disorders, enhancement of bone marrow transplantation, and treatment of other IL-6 related conditions are provided.
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: May 20, 2008
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: Michel Revel, Judith Chebath, Tsvee Lapidot, Orit Kollet
  • Enhancement of oligodendrocyte differrentiation
    Publication number: 20070237748
    Abstract: The present invention is generally in the field of neurological diseases and disorders, particular in the field of neurodegenerative diseases in which the myelin cover of nerves is lost. IL6R/IL6 chimera is used to promote the formation of oligodendrocytes from embryonic stem cells for treatment of neurodegenerative diseases or posttraumatic nerve damage.
    Type: Application
    Filed: June 13, 2004
    Publication date: October 11, 2007
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Michel Revel, Judith Chebath, Peter Lonai
  • IFN receptor 1 binding proteins, DNA encoding them, and methods of modulating cellular response to interferons
    Patent number: 7264945
    Abstract: Novel proteins IR1B1 and IR1B4 have been isolated which bind to the type I IFN receptor IFNAR1 and function in the cellular response to IFNs. DNA encoding such proteins in either the sense or anti-sense orientation can be administered to either enhance or inhibit the cellular response to IFNs. Antibodies to the proteins can be used for isolation of the new protein or for immunodetection thereof.
    Type: Grant
    Filed: December 4, 2002
    Date of Patent: September 4, 2007
    Assignee: Yeda Research and Development Co. Ltd
    Inventors: Michel Revel, Carolina Abramovitch, Judith E. Chebath
  • Chimeric Interleukin-6 Soluble Receptor/Ligand Protein, Analogs Thereof and Uses Thereof
    Publication number: 20070172455
    Abstract: Chimeric proteins constructed from the fusion of the naturally occurring form of the soluble IL-6 receptor and IL-6 which are useful for treatment of cancer and liver disorders, enhancement of bone marrow transplantation, and treatment of other IL-6 related conditions are provided.
    Type: Application
    Filed: March 20, 2007
    Publication date: July 26, 2007
    Applicant: Yeda Research and Development Co., Ltd.
    Inventors: Michel Revel, Judith Chebath, Tsvee Lapidot, Orit Kollet
  • IL6RIL6 chimera for the treatment of neurodegenerative diseases
    Patent number: 7201896
    Abstract: The invention relates to the use of IL6RIL6 chimera in the treatment and prevention of neurological diseases and disorders.
    Type: Grant
    Filed: June 21, 2000
    Date of Patent: April 10, 2007
    Assignees: Yeda Research and Development Company Ltd., Applied Research Systems ARS Holding N.V.
    Inventors: Michel Revel, Judith Chebath, Marina Pizzi, PierFranco Spano, Ursula Boschert
  • Chimeric interleukin-6 soluble receptor/ligand proteins
    Patent number: 7198781
    Abstract: Chimeric proteins constructed from the fusion of the naturally occurring form of the soluble IL-6 receptor and IL-6 which are useful for treatment of cancer and liver disorders, enhancement of bone marrow transplantation, and treatment of other IL-6 related conditions are provided.
    Type: Grant
    Filed: July 9, 1998
    Date of Patent: April 3, 2007
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: Michel Revel, Judith Chebath, Tsvee Lapidot, Orit Kollet
  • Novel IFN receptor 1 binding proteins, DNA encoding them, and methods of modulating cellular response to interferons
    Publication number: 20060147436
    Abstract: Novel proteins IR1B1 and IR1B4 have been isolated which bind to the type I IFN receptor IFNAR1 and function in the cellular response to IFNs. DNA encoding such proteins in either the sense or anti-sense orientation can be administered to either enhance or inhibit the cellular response to IFNs. Antibodies to the proteins can be used for isolation of the new protein or for immunodetection thereof.
    Type: Application
    Filed: February 9, 2006
    Publication date: July 6, 2006
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Michel Revel, Carolina Abramovitch, Judith Chebath
  • Use of il6r/il6 chimera in nerve cell regeneration
    Publication number: 20050220761
    Abstract: The present invention provides for the use of IL6R/IL6 chimera for the manufacture of medicaments for the treatment of neurological diseases and disorders.
    Type: Application
    Filed: December 31, 2002
    Publication date: October 6, 2005
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.
    Inventors: Shalom Haggiag, Michel Revel, Judith Chebath, Alon Levy, Peilin Zhang
  • Novel IFN receptor 1 binding proteins, DNA encoding them, and methods of modulating cellular response to interferons
    Publication number: 20030176678
    Abstract: Novel proteins IR1B1 and IR1B4 have been isolated which bind to the type I IFN receptor IFNAR1 and function in the cellular response to IFNs. DNA encoding such proteins in either the sense or anti-sense orientation can be administered to either enhance or inhibit the cellular response to IFNs. Antibodies to the proteins can be used for isolation of the new protein or for immunodetection thereof.
    Type: Application
    Filed: December 4, 2002
    Publication date: September 18, 2003
    Inventors: Michel Revel, Carolina Abramovitch, Judith E. Chebath
  • Novel IFN receptor 1 binding proteins, DNA encoding them, and methods of modulating cellular response to interferons
    Publication number: 20020119129
    Abstract: Novel proteins IR1B1 and IR1B4 have been isolated which bind to the type I IFN receptor IFNAR1 and function in the cellular response to IFNs. DNA encoding such proteins in either the sense or anti-sense orientation can be administered to either enhance or inhibit the cellular response to IFNs. Antibodies to the proteins can be used for isolation of the new protein or for immunodetection thereof.
    Type: Application
    Filed: April 1, 2002
    Publication date: August 29, 2002
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Michel Revel, Carolina Abramovitch, Judith E. Chebath
  • Synthetic peptides that inhibit IL-6 activity
    Patent number: 6172042
    Abstract: Novel peptides derived from the gp80 subunit of the IL-6 receptor system which inhibit the activity of IL-6 are provided.
    Type: Grant
    Filed: September 2, 1998
    Date of Patent: January 9, 2001
    Assignee: Yeda Research and Development Co. LTD
    Inventors: Judith Chebath, Robert Halimi, Michel Revel
  • Antitumor pharmaceutical composition comprising IL-6 transfected cells
    Patent number: 5902576
    Abstract: An anti-tumor pharmaceutical composition includes cells into which a gene encoding human IL-6 has been inserted. A method of treatment of a patient suffering from cancer to prevent and/or inhibit the development of metastases by administering to the patient the anti-tumor pharmaceutical composition including the above mentioned cells.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: May 11, 1999
    Assignee: YEDA Research and Development Co. Ltd. at Weizmann Institute of Science
    Inventors: Lea Eisenbach, Angel Porgador, Michael Feldman, Michel Revel
  • Recombinant production of interferon-gamma binding proteins
    Patent number: 5763210
    Abstract: A cDNA encoding a new interferon-gamma (IFN-.gamma.)-binding protein is disclosed. Methods and products for the recombinant production of the protein are provided, and specific antibodies are also described.
    Type: Grant
    Filed: March 3, 1994
    Date of Patent: June 9, 1998
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Daniela Novick, Yves Mory, Dina G. Fischer, Michel Revel, Menachem Rubinstein
  • Soluble interferon .alpha.-receptor, its preparation and use
    Patent number: 5643749
    Abstract: New forms of interferon .alpha.-receptors are provided. They may be prepared recombinantly and may be used in diagnosis and therapy.
    Type: Grant
    Filed: October 24, 1994
    Date of Patent: July 1, 1997
    Assignee: Yeda Research and Development Co, Ltd.
    Inventors: Michel Revel, Carolina Abramovich, Edward Ratovitski
  • Soluble IFN-.beta.2/IL-6 binding protein its preparation, and pharmaceutical compositions containing it
    Patent number: 5621077
    Abstract: Human natural IFN-.beta.2/IL-6 receptor and its soluble extracellular fragment are provided in substantially purified form and are shown to stimulate and to enhance beneficial effects of IFN-.beta.2/IL-6, such as its antiproliferative activity. Polyclonal and monoclonal antibodies raised against the soluble fragment of the receptor are also provided.
    Type: Grant
    Filed: October 27, 1994
    Date of Patent: April 15, 1997
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Daniela Novick, Louise Chen, Hartmut Engelmann, Michel Revel, Menachem Rubinstein, David Wallach